MedTrace Logo

Prostate Margin Reduction to Reduce Acute Rectal Toxicity (PROTRACT)

NCT04004858 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-07-05

No results posted yet for this study

Summary

The objectives of this study are:

1. Retrospectively validate a reduced margin schema for intermediate risk prostate hypofractionated VMAT treatments
2. Demonstrate in a prospective pilot clinical trial that patients planned and treated with the reduced margin schema will have reduced acute rectal toxicity

Conditions

Interventions

RADIATION

External beam radiation therapy

Patient will receive 60Gy in 20 fractions as per standard practice

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    collaborator OTHER

  • University Health Network, Toronto

    collaborator OTHER

  • Southlake Regional Health Centre

    lead OTHER

Principal Investigators

  • Beibei Zhang, PhD · Southlake Regional Health Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2020-08-01
Completion
2021-08-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04004858 on ClinicalTrials.gov